How do you determine whether to treat a young adult with stage IA Hodgkin Lymphoma with the adult or pediatric treatment paradigm?

There is a long history of pediatric protocols for HL differing somewhat from the adult ones, but not much biologic rationale to support this, as the disease in young adults is biologically the same as in pediatric patients. Side effects of RX may of course differ, particularly with regards to RT an...

Assuming it was classical HL, I would consider the extent of disease and the potential long term side effects of using ISRT. If the patient was post-pubescent (i.e. fully grown) and the RT dose to the heart and breast tissue (in a female) were to be low, I would strongly consider ABVDx2+20 Gy per GH...